www.fdanews.com/articles/82157-oxford-biomedica-seeks-to-raise-up-to-30-mln-stg
OXFORD BIOMEDICA SEEKS TO RAISE UP TO 30 MLN STG
November 3, 2005
Britain's Oxford Biomedica (OXB.L: Quote, Profile, Research) said on Wednesday it planned to raise up to 30 million pounds ($53 million)in a placing and open offer of its shares to fund final stage clinical trials of its key drug, TroVax for cancer. The company said it planned to start a final Phase III clinical trial in 2006 and that it was in talks with potential commercial partners for the experimental medicine.